Welcome to our dedicated page for Harvard Biosci SEC filings (Ticker: HBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harvard Bioscience, Inc. (HBIO) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including Forms 10‑K, 10‑Q, 8‑K and other key documents. Harvard Bioscience is a developer, manufacturer and seller of technologies, products and services used in life science research, drug and therapy discovery, bio‑production and preclinical testing. Its filings provide detailed information on this business, its financial condition and its capital structure.
Through annual reports on Form 10‑K and quarterly reports on Form 10‑Q, Harvard Bioscience presents audited and interim financial statements, segment and product discussions, risk factors, management’s discussion and analysis, and information on liquidity and capital resources. These filings give investors and analysts insight into revenues, margins, operating expenses, cash flows and balance sheet items, as well as commentary on trends affecting its life science tools business.
Current reports on Form 8‑K are especially important for tracking material events at Harvard Bioscience. In 2025, the company used 8‑K filings to disclose amendments to its credit agreement, a new Loan and Security Agreement with BroadOak that introduced term loans and a convertible term loan, the issuance of warrants, Nasdaq listing and compliance notices, audit committee composition matters, retention arrangements with executives, and the announcement of quarterly financial results and conference calls. These 8‑K filings also document board appointments and CEO succession plans.
On this page, Stock Titan provides real‑time access to new HBIO filings as they appear on EDGAR, along with AI‑generated summaries that explain the core points of each document in plain language. For example, AI summaries can highlight covenant changes and going‑concern language in credit‑related filings, outline the structure of new financing arrangements, or extract key performance metrics from earnings releases furnished on Form 8‑K. Users can also review insider transaction reports on Form 4 when available, to see equity awards or share transactions by directors and officers as disclosed in SEC filings.
By consolidating Harvard Bioscience’s 10‑K, 10‑Q, 8‑K and other SEC forms with AI‑assisted analysis, this page helps readers understand how the company reports on its life science tools operations, capital structure, Nasdaq listing status and governance changes over time, without having to parse every filing manually.
Harvard Bioscience Chief Financial Officer Mark T. Frost reported an equity compensation grant rather than a market trade. He acquired 30,000 restricted stock units (RSUs) at no cost, which will vest in three equal installments on March 20, 2027, 2028, and 2029, subject to his award agreement. After this grant, he is shown with 47,500 common stock equivalents, including 5,000 shares purchased on March 16, 2026, 10,000 additional RSUs scheduled to vest on May 12, 2026, and 2,500 shares of common stock beneficially owned. The filing also notes that these RSU and share counts were adjusted to reflect a 10-for-1 reverse stock split that took effect on March 13, 2026.
Harvard Bioscience Chief Financial Officer Mark T. Frost bought 5,000 shares of common stock in an open-market purchase at $5.00 per share. Following this transaction, he directly owns a total of 17,500 shares, including 10,000 restricted stock units scheduled to vest on May 12, 2026.
Duke John D reported acquisition or exercise transactions in this Form 4 filing.
HARVARD BIOSCIENCE INC reported that Chief Executive Officer and director John D. Duke received a grant of 75,000 shares of Common Stock on 2026-03-20. The award was reported at a price of $0.0000 per share, indicating a compensation-related grant rather than a market purchase. Following this transaction, his directly owned Common Stock holdings increased to 180,000 shares.
BroadOak Income Fund, BroadOak Fund VI, BroadOak Capital Partners, and William Snider report significant ownership in Harvard Bioscience common stock. Mr. Snider is deemed to beneficially own 846,000 shares, or 15.97% of the company, based on 4,471,989 shares outstanding as of March 5, 2026, including shares underlying warrants and a convertible loan.
The position arises from a senior secured Loan and Security Agreement under which Harvard Bioscience obtained three term loans of $10.0 million, $22.5 million, and $7.5 million. The Term C Loan is convertible into common stock at $10.00 per share and can automatically convert if the share price exceeds $15.00 for thirty consecutive trading days. Lenders also received seven‑year warrants for 200,000 shares at a $5.00 exercise price and an effective resale registration statement.
The loans bear interest at not less than 12.80% per year initially, include prepayment premiums and a 10.00% exit fee on repaid amounts, and are secured by substantially all assets of Harvard Bioscience and its guarantor subsidiaries. Proceeds are used to refinance the prior credit facility, pay transaction costs, and support working capital and general corporate purposes. BroadOak, through the administrative agent, obtained the right to nominate one director; Mr. Snider has been appointed to the board and its compensation committee and may receive director compensation and equity awards. He also purchased 21,000 shares in open‑market transactions in March 2026 with personal funds.
Harvard Bioscience director Stephen J. Denelsky bought 10,000 shares of common stock in an open-market transaction at $4.87 per share. After this purchase on March 17, 2026, he directly holds 21,000 shares, including 11,000 restricted stock units scheduled to fully vest on September 5, 2026.
The footnotes also note that on March 13, 2026, Harvard Bioscience completed a 10-for-1 reverse stock split, and the 11,000 restricted stock units were adjusted from a previously reported 110,000 units to reflect this split.
Harvard Bioscience director William Snider reported open-market purchases of company stock. On March 16, 2026, he bought 12,525 shares of common stock at a weighted average price of $4.99 per share, with actual trade prices ranging from $4.80 to $4.95. On March 17, 2026, he bought an additional 8,475 shares at a weighted average price of $4.85, with individual trades between $4.85 and $5.00. Following these transactions, he directly holds 32,000 shares of common stock, plus 11,000 restricted stock units that fully vest on December 17, 2026. The filing notes a 10-for-1 reverse stock split of Harvard Bioscience common stock on March 13, 2026, which reduced the previously reported 110,000 restricted stock units to 11,000.
Harvard Bioscience Chief Executive Officer John D. Duke bought 5,000 shares of common stock in an open-market purchase at $5.01 per share on March 16, 2026, bringing his directly held common stock to 105,000 shares.
His reported holdings include 50,000 restricted stock units that vest in three equal installments on August 8, 2026, 2027 and 2028, plus 50,000 performance-based RSUs that may vest based on relative total shareholder return versus the Russell 2000 index over the period from August 8, 2025 to the earlier of July 30, 2028 or a change of control, with a maximum payout of 150% of the target RSU amount. The RSU figures have been adjusted to reflect a 10-for-1 reverse stock split on March 13, 2026.
Harvard Bioscience furnished an investor presentation outlining recent performance, strategy, and 2026 outlook. For FY25, the company reports $87M revenue, 58% adjusted gross margin, $8M adjusted EBITDA, and a GAAP net loss of $56.7M, driven in part by a goodwill impairment.
The business generated 54% recurring revenue in 2025 from consumables, software, and services and targets a path toward 60%. Guidance for FY26 calls for 2–4% revenue growth, 58–60% adjusted gross margin, and 6–10% adjusted EBITDA growth, with 1Q26 revenue expected between $20–$22M.
The presentation highlights debt refinancing that extends maturity to 2029 and reduces annual debt service by $3M, as well as a phased closure of the Holliston, MA plant, which is expected to improve adjusted EBITDA by about $3M in 2027 and $4M annually beginning in 2028. Management emphasizes a focus on translational science tools, recurring revenue expansion, and new products such as MeshMEA, SoHo, and Incub8.
Harvard Bioscience, Inc. reports 2025 revenues of $86.6 million, down from $94.1 million in 2024, as demand softened from distributors, CROs and academic research customers. Gross margin slipped slightly to 57.7%.
The company recorded a non-cash goodwill impairment of $48.0 million, driving a large operating loss. Operating expenses were reduced across sales, G&A and R&D, and a UK pension plan was fully settled, triggering a $1.2 million non-cash charge.
In January 2026, Harvard Bioscience launched Project Viking, a manufacturing consolidation that will close the Holliston, MA plant and shift production to Minneapolis and European sites. The plan is expected to generate about $3 million in cost savings in 2027 and $4 million annually from 2028, with estimated pre-tax restructuring charges of $3.4–$4.4 million.
Debt remains significant with $40.0 million outstanding and cash of $8.6 million at year-end 2025. A new 2025 Loan Agreement refinanced prior facilities and removed prior going-concern doubt, but covenants require minimum liquidity and adjusted EBITDA.
The company also faces listing pressure: after failing Nasdaq’s $1.00 minimum bid price on the Global Market, shares were transferred to the Nasdaq Capital Market and a 1-for-10 reverse stock split was approved, effective March 13, 2026, to help regain compliance.
Harvard Bioscience reported softer 2025 results driven by a large non-cash goodwill charge. Q4 2025 revenue was $23.7 million, slightly below $24.6 million a year earlier, but gross margin improved to 59.7% from 57.1%. Q4 net loss was $2.8 million versus breakeven, while adjusted EBITDA rose to $3.8 million from $3.0 million.
For full-year 2025, revenue declined to $86.6 million from $94.1 million amid weaker spending by CROs, distributors and academic customers. Net loss widened sharply to $56.7 million from $12.4 million, primarily due to a $48.0 million goodwill impairment, plus refinancing and pension settlement costs. Adjusted EBITDA improved to $8.1 million from $7.2 million, and cash from operations increased to $6.7 million from $1.4 million, reflecting better underlying cash generation despite the accounting loss.
Year-end 2025 cash was $8.6 million versus $4.1 million, debt was $35.9 million, and stockholders’ equity fell to $13.7 million from $63.3 million after the impairment. Management highlighted a strategic shift toward higher-margin translational science and New Approach Methodologies, aiming to support growth in 2026.